Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Senescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · cited 1×
“3c , d ), in contrast to previous reports using mice with functional p16 Ink4a , in which Arf was almost invariably los”
ResultTumor surveillance via the ARF–p53 pathway
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 717
Targeted disruption of the three Rb-related genes leads to loss of G 1 control and immortalization
Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S., Williams, B., Theodorou, E., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.843200 · Cited by 582 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundThe INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533 · cited 1×
“Although most mutations at the CDKN2A locus found in human tumours result in disruption of both the ARF and INK4A transcripts, the presence of point mutations and small deletions that specifically affect p16 INK4a strongly implicate p16 INK4a as a tumour suppresso”
Background(1993) · PubMed · Cited by 469
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458 · cited 1×
“, unpublished data), and previous observations that Rb1 heterozygosity also fails to significantly collaborate with Eµ- Myc in tumorigenesi”
BackgroundDannenberg, J.-H., van Rossum, A., Schuijff, L., & te Riele, H. (2000) · Genes & Development · doi:10.1101/gad.847700 · Cited by 413
(1999) · PubMed · Cited by 338
p107 is a suppressor of retinoblastoma development in pRb-deficient mice
Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.-L., Jeanny, J.-C., Dannenberg, J.-H., Berns, A., & te Riele, H. (1998) · Genes & Development · doi:10.1101/gad.12.11.1599 · Cited by 320
Self-citationCellular senescence as a tumor-protection mechanism: the essential role of counting
Wright, W. E., & Shay, J. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00163-5 · Cited by 306
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization
Carnero, A., Hudson, J. D., Price, C. M., & Beach, D. H. (2000) · Nature Cell Biology · doi:10.1038/35004020 · Cited by 279
Methylation Silencing and Mutations of the p14ARF and p16INK4a Genes in Colon Cancer
Burri, N., Shaw, P., Bouzourene, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D., Bosman, F. T., & Chaubert, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780230 · Cited by 181
Escape from premature senescence is not sufficient for oncogenic transformation by Ras
Peeper, D. S., Dannenberg, J., Douma, S., Riele, H. T., & Bernards, R. (2001) · Nature Cell Biology · doi:10.1038/35055110 · Cited by 112
Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma
Arap, W., Knudsen, E. S., Wang, J. Y. J., Cavenee, W. K., & Huang, H.-J. S. (1997) · Oncogene · doi:10.1038/sj.onc.1200870 · Cited by 33
Rizos, H., Becker, T. M., Holland, E. A., Kefford, R. F., & Mann, G. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201217 · Cited by 23
Cited by
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
“Genetic disruption of the gene encoding p16INK4A predisposes mice and humans to tumorigenesis, includ- ing melanoma (Gruis et al. 1995; Krimpenfort et al. 2001; Sharpless et al. 2001).”
BackgroundSelf-citationCellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774
“Interfering with pathways that can induce senescence-associated replicative arrest are likely to promote cancer, as occurs when p16 INK4a , the retinoblastoma (Rb) protein, or p53 is diminished or inactivated (67, 103).”
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
“On the other hand, mice with decreased levels of p16INK4a are tumor prone, and this precludes the analysis of aging (Krimpenfort et al., 2001; Sharpless et al., 2001).”
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Yet, mice lacking p16Ink4a, in particular, are tumor prone and develop a wide spectrum of cancers, particularly after exposure to chemical carcinogens or X-rays (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.